Original ArticleLong-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Keywords
Abbreviations and Acronyms
Cited by (0)
Supplemental material available at www.aaojournal.org.
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. The author(s) have made the following disclosure(s): E.B.S.: Steering committee – AbbVie; Consultant – AbbVie, Clearside, EyeGate, EyePoint, Eyevensys, Gilead, Inotek, Mallinckrodt, Santen, XOMA; Financial support – AbbVie, Aldeyra, Bristol-Myers Squibb, Clearside, EyeGate, EyePoint, Genentech, Novartis. G.J.J.: Consultant – AbbVie, EyePoint Pharmaceuticals, Eyevensys. E.F.: Advisory board and Consultant – AbbVie, Alcon, Allergan; Financial support – AbbVie, Allergan, Gilead. L.L.L.: Advisory board and Consultant – AbbVie, Allergan, Bayer; Financial support – Bayer. P.T.M.: Steering committee – VISUAL studies; Consultant and Advisory board – Alimera, Allergan, EyePoint, Santen; Financial support – AbbVie, Clearside, Gilead, Santen. A.D.D.: Advisory board – AbbVie. A.P.B.: Advisory board and Consultant – AbbVie. Q.D.N.: Scientific advisory board – AbbVie, Bausch & Lomb, Santen, XOMA; Steering committee – VISUAL studies. J.E.T.: Scientific advisory board – AbbVie, Clearside, Santen; Consultant – Gilead, Nightstarx; Financial support – Allergan. J.V.C.: Financial support – Novartis, AbbVie, Allergan, Bayer, DORC, MSD, Novartis, Santen, Zeiss; Nonfinancial support – AbbVie, Allergan, Bayer, DORC, Novartis. L.C.: Consultant – AbbVie, Santen. A.A.: Advisory board – AbbVie, Allergan, Santen. H.G.: Advisory board – AbbVie. T.K.: Advisory board - AbbVie. M.K.: Consultant – AbbVie. A.T.V.: Consultant – AbbVie, Roche. M.K.: Employee – AbbVie Deutschland GmbH & Co. KG. A.P.S.: Employee – AbbVie. J.L.: Employee – AbbVie. S.P.: Former employee – AbbVie. K.M.D.: Employee – AbbVie. A.S.: Advisory board – AbbVie. C.M.: Consultant – AbbVie. M.E.J.V.V.: Lecturer – AbbVie Netherlands, Bayer Netherlands, Novartis Netherlands; Financial support – Allergan Europe. M.Z.: Scientific advisory board – AbbVie, Santen. J.T.R.: Consultant – AbbVie, Celldex, Corvus, Eyevensys, Genentech, Gilead, Horizon, Janssen, Novartis, Regeneron, Roche, Santen, Topivert, UCB; Financial support – Pfizer; Royalties – UpToDate
Sponsored by AbbVie, Inc., North Chicago, Illinois. The sponsor participated in study design and conduct; data management, analysis, and interpretation; and manuscript preparation, review, and approval. Medical writing support was provided by Catherine DeBrosse, PhD, of ICON (North Wales, PA), and was funded by AbbVie Inc.
Data Sharing: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided after review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time, and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.
HUMAN SUBJECTS: Human subjects were included in this study. Protocol approval was obtained from appropriate review boards before study initiation. All research adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were included in this study.
Author Contributions:
Conception and design: N/A
Analysis and interpretation: Suhler, Jaffe, Fortin, Lim, Merrill, Dick, Brezin, Nguyen, Thorne, Van Calster, Cimino, Adan, Goto, Kaburaki, Kramer, Vitale, Kron, Song, Liu, Pathai, Douglas, Schlaen, Muccioli, Van Velthoven, Zierhut, Rosenbaum
Data collection: Suhler, Jaffe, Fortin, Lim, Merrill, Dick, Brezin, Nguyen, Thorne, Van Calster, Cimino, Adan, Goto, Kaburaki, Kramer, Vitale, Schlaen, Muccioli, Van Velthoven, Zierhut, Rosenbaum
Obtained funding: Suhler, Fortin, Lim, Merrill, Thorne, Van Calster, Van Velthoven, Rosenbaum; Study was performed as part of the authors' regular employment duties. No additional funding was provided.
Overall responsibility: Suhler, Jaffe, Fortin, Lim, Merrill, Dick, Brezin, Nguyen, Thorne, Van Calster, Cimino, Adan, Goto, Kaburaki, Kramer, Vitale, Kron, Song, Liu, Pathai, Douglas, Schlaen, Muccioli, Van Velthoven, Zierhut, Rosenbaum